. Author manuscript; available in PMC: 2013 May 1.

Published in final edited form as: Pediatr Blood Cancer. 2011 May 31;58(5):729–735. doi: 10.1002/pbc.23157

Table II.

Enhancement of Rapamycin with IMC-A12

Xenograft	IMC-A12 T-C	RAP T-C	RAP+IMC T-C	P-value [combination vs. RAP]	P-value [combination vs. IMC-A12]	Therapeutic Enhancement

EW5	12.6	10.7	60.1	<0.01	<0.01	YES
EW5	(PD2)	(PD2)	(PR)	<0.01	<0.01	YES

Rh28	>64.8	20.8	>64.8	<0.01	0.44	NE
Rh28	(MCR)	(PD2)	(MCR)	<0.01	0.44	NE

Rh30	5.8	7.5	11.1	0.77	<0.01	NO
Rh30	(PD2)	(PD2)	(PD2)	0.77	<0.01	NO

Rh41	36.0	8.8	50.3	<0.01	0.03	NO
Rh41	(PD2)	(PD2)	(CR)	<0.01	0.03	NO

GBM2	0.1	20.6	22.4	0.84	<0.01	NO
GBM2	(PD1)	(PD2)	(PD2)	0.84	<0.01	NO

NB-EBc1	7.2	6.6	17.2	0.04	0.07	NO
NB-EBc1	(PD2)	(PD2)	(PD2)	0.04	0.07	NO

NB-1643	59.4	5.4	70.8	<0.01	0.10	NO
NB-1643	(CR)	(PD2)	(CR)	<0.01	0.10	NO

OS-2	26.2	21.7	38.3	<0.01	<0.01	YES
OS-2	(PD2)	(PD2)	(PD2)	<0.01	<0.01	YES

OS-9	14.5	15.8	31.0	<0.01	<0.01	YES
OS-9	(PD2)	(PD2)	(PD2)	<0.01	<0.01	YES